Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy

20260 citationsJournal Articlegold Open Access

Authors

Caroline J Coats · University of Glasgow

Theodore Abraham · University of California, San Francisco

Roberto Barriales-Villa · Instituto de Investigación Biomédica de A Coruña

Michael Arad · Sheba Medical Center

Nuno Cardim · Companhia União Fabril

Brian L Claggett · Brigham and Women's Hospital

H-D Düngen ·

Abstract

In SEQUOIA-HCM, the dosing, safety, and treatment effects of aficamten were consistent across geographic regions despite differences in baseline characteristics of patients with oHCM.

Topics & Keywords

Cardiomyopathy and Myosin Studies Cardiovascular Function and Risk Factors Cardiovascular Effects of Exercise

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: ESC Heart Failure

DOI: 10.1093/eschf/xvag023

Field-Weighted Citation Impact: 0.00